We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · December 26, 2022

Clinical and Molecular Response to Tebentafusp in Patients With Previously Treated Metastatic Uveal Melanoma

Nature Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Nature Medicine
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
Nat. Med. 2022 Nov 01;28(11)2364-2373, RD Carvajal, MO Butler, AN Shoushtari, JC Hassel, A Ikeguchi, L Hernandez-Aya, P Nathan, O Hamid, JM Piulats, M Rioth, DB Johnson, JJ Luke, E Espinosa, S Leyvraz, L Collins, HM Goodall, K Ranade, C Holland, SE Abdullah, JJ Sacco, T Sato

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading